Epalrestat is a selective aldose reductase inhibitor. Since its approval in Japan in 1992, it has been mainly used for the treatment of diabetic peripheral neuropathy. Similar to other medications, Epalrestat also carries certain risks of adverse reactions and limitations in its use.
What Are the Side Effects of Epalrestat?
Common Side Effects
Allergic Reactions: Some patients may experience symptoms such as skin rashes, itching, erythema, or blisters, but the incidence rate is extremely low.
Gastrointestinal Discomfort: Common symptoms include abdominal pain and nausea; individual patients may experience vomiting, diarrhea, loss of appetite, abdominal distension, or constipation, occasionally accompanied by heartburn.
Impact on Liver Function: Clinical reports have indicated mild elevations in the levels of AST (aspartate aminotransferase), ALT (alanine aminotransferase), or γ-GTP (γ-glutamyl transferase); a small number of patients may experience elevated bilirubin.
Kidney-Related Reactions: Increased BUN (blood urea nitrogen) or creatinine levels have been observed in a small number of cases; some patients may be accompanied by reduced urine output or frequent urination.
Hematological Abnormalities: A very small number of patients may develop anemia or leukopenia.
Other Common Reactions: Individual patients may feel fatigue, dizziness, headache, or stiffness and pain in the limbs; symptoms such as chest discomfort, palpitations, edema, or hot flashes may also occur.
Severe Side Effects of Epalrestat
Thrombocytopenia
The incidence frequency is unknown, but it is classified as a major side effect.
Patients may develop bleeding tendencies, such as skin ecchymosis, nosebleeds, or gingival bleeding. Immediate blood routine tests and corresponding medical measures are required.
Severe Hepatitis and Liver Failure
These include abnormal liver function, jaundice, and liver failure; the incidence frequency is unknown or < 0.1%.
If a patient experiences persistent fatigue, a significant decrease in appetite, darkening of urine color, or yellowing of the skin and sclera, urgent liver function tests and an assessment of the necessity of discontinuing the medication are required.
Risk of Aggravated Allergic Reactions
If a skin rash spreads rapidly, accompanied by difficulty breathing or mucosal edema, vigilance should be maintained for the possibility of severe allergic reactions (such as anaphylactic shock), and immediate medical intervention is necessary.
Precautions for Taking Epalrestat
Medication Administration and Packaging Warnings
Safety of PTP Packaging: Tablets must be removed from the aluminum foil blister before taking. If the aluminum foil is accidentally swallowed, its sharp edges may pierce the esophageal mucosa, leading to life-threatening complications such as perforation and mediastinitis.
Individualized Dosage: The usual adult dosage is 50mg each time, three times a day, taken orally before each meal. The dosage may be appropriately adjusted based on age and symptoms, but this must be done under the guidance of a doctor.
Tips on Interference with Clinical Tests
After taking the medication, urine may turn yellowish-brown or red. This color change may affect the interpretation of the results of qualitative tests for urinary bilirubin and ketone bodies.
Patients should inform the doctor that they are taking Epalrestat before undergoing laboratory tests.
Medication for Special Populations
Pregnant Women: The medication should be used only when the therapeutic benefits outweigh the potential risks.
Lactating Women: A comprehensive consideration of the necessity of treatment and the benefits of breastfeeding should be made to decide whether to continue breastfeeding or discontinue the medication. Animal studies have shown that the drug can be excreted in breast milk.
Children: No clinical trials in children have been conducted, and its effectiveness has not been established.
Elderly Patients: The dosage may be adjusted according to age, but close monitoring for adverse reactions is required.
Patients with Hepatic or Renal Impairment: Although specific guidelines have not been clearly stated in the package insert, liver dysfunction is a known side effect, so close monitoring of liver function indicators is necessary.
